ATTEMPTS system: A macromolecular prodrug strategy for cancer drug delivery

Current Pharmaceutical Design

Volumn 16, Issue 21, 2010, Pages 2369-2376

  Huang, Yongzhuo ^a   Park, Yoon Shin ^a   Wang, Jianxin ^a   Moon, Cheol ^a   Kwon, Young Min ^a   Chung, Hee Sun ^a   Park, Yoon Jeong ^a   Yang, Victor C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

ATTEMPTS; Cancer; Cell penetrating peptide; CPP; Prodrug; Protein drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CAMPTOTHECIN; CELL PENETRATING PEPTIDE; DOXORUBICIN; GELONIN; HEPARIN; LIPOSOME; POLYELECTROLYTE; POLYMER; PROTAMINE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL PERMEABILIZATION; CONTROLLED DRUG RELEASE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HEPARIN; HUMANS; MACROMOLECULAR SUBSTANCES; PRODRUGS; PROTAMINES;

EID: 77955599946     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791920441     Document Type: Review

References (57)

1. Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 2008; 15: 1802-26.
2. Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Des 2009; 15: 2236-50.
3. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004; 27: 85-131.
4. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55: 1179-88.
5. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-93.
6. Mano M, Teodosio C, Paiva A, et al. On the mechanisms of the internalization of S4(13)-PV cell-penetrating peptide. Biochem J 2005; 390: 603-12.
7. Chang M, Chou JC, Chen CP, et al. Noncovalent protein transduction in plant cells by macropinocytosis. New Phytol 2007; 174: 46-56.
8. Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-72.
9. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994; 91: 664-8.
10. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008; 1786(2): 126-38.
11. Dietz GP, Bahr M. Peptide-enhanced cellular internalization of proteins in neuroscience. Brain Res Bull 2005; 68: 103-14.
12. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157(2): 195-206.
13. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-5.
14. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 2005; 102: 247-53.
15. Mann DA, Frankel AD. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 1991; 10: 1733-9.
16. Rusnati M, Coltrini D, Oreste P, et al. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem 1997; 272: 11313-20.
17. Rusnati M, Tulipano G, Urbinati C, et al. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J Biol Chem 1998; 273: 16027-37.
18. Tyagi M, Rusnati M, Presta M, et al. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001; 276: 3254-61.
19. Hakansson S, Jacobs A, Caffrey M. Heparin binding by the HIV-1 tat protein transduction domain. Protein Sci 2001; 10: 2138-9.
20. Hakansson S, Caffrey M. Structural and dynamic properties of the HIV-1 tat transduction domain in the free and heparin-bound states. Biochemistry 2003; 42: 8999-9006.
21. Ziegler A, Seelig J. Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys J 2004; 86: 254-63.
22. Silhol M, Tyagi M, Giacca M, et al. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur J Biochem 2002; 269: 494-501.
23. Thoren PE, Persson D, Karlsson M, et al. The antennapedia peptide penetratin translocates across lipid bilayers - the first direct observation. FEBS Lett 2000; 482: 265-8.
24. Magzoub M, Pramanik A, Graslund A. Modeling the endosomal escape of cell-penetrating peptides: transmembrane pH gradient driven translocation across phospholipid bilayers. Biochemistry 2005; 44: 14890-7.
25. Liang JF, Park YJ, Song H, et al. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs. J Control Release 2001; 72: 145-56.
26. Byun Y, Yang VC. Delivery system for targeted thrombolysis without the risk of hemorrhage. ASAIO J 1998; 44: M638-41.
27. Liang JF, Li YT, Song H, et al. ATTEMPTS: a heparin/protaminebased delivery system for enzyme drugs. J Control Release 2002; 78: 67-79.
28. Naik SS, Liang JF, Park YJ, et al. Application of ATTEMPTS for drug delivery. J Control Release 2005; 101: 35-45.
29. Park YJ, Liang JF, Song H, et al. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects. Adv Drug Deliv Rev 2003; 55: 251-65.
30. Yang VC, Naik SS, Song H, et al. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis. J Control Release 2005; 110: 164-76.
31. Chang LC, Lee HF, Yang Z, et al. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. AAPS PharmSci 2001; 3: E17.
32. Moon C, Kwon YM, Lee WK, et al. In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cellpenetrating peptide. J Control Release 2007; 124: 43-50.
33. Park YJ, Chang LC, Liang JF, et al. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J 2005; 19: 1555-7.
34. Park YJ, Liang JF, Ko KS, et al. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J Gene Med 2003; 5: 700-11.
35. Moon C, Kwon YM, Lee WK, et al. A novel polyrotaxane-based intracellular delivery system for camptothecin: in vitro feasibility evaluation. J Biomed Mater Res A 2008; 84: 238-46.
36. Choi YS, Lee JY, Suh JS, et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010; 31: 1429-43.
37. Park YS, Huang Y, Park YJ, et al. Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide. J Control Release 2010; 144(1): 82-90.
38. Chang LC, Liang JF, Lee HF, et al. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity. AAPS PharmSci 2001; 3: E18.
39. Lee LM, Chang LC, Wrobleski S, et al. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci 2001; 3: E19.
40. Liang JF, Zhen L, Chang LC, et al. A less toxic heparin antagonist--low molecular weight protamine. Biochemistry (Mosc) 2003; 68: 116-20.
41. Tsui B, Singh VK, Liang JF, et al. Reduced reactivity towards antiprotamine antibodies of a low molecular weight protamine analogue. Thromb Res 2001; 101: 417-20.
42. Kwon YM, Li YT, Liang JF, et al. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J Control Release 2008; 130: 252-8.
43. Atkinson SF, Bettinger T, Seymour LW, et al. Conjugation of folate via gelonin carbohydrate residues retains ribosomalinactivating properties of the toxin and permits targeting to folate receptor positive cells. J Biol Chem 2001; 276: 27930-5.
44. Stirpe F, Olsnes S, Pihl A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 1980; 255: 6947-53.
45. Kwon YM, Li Y, Naik S, et al. The ATTEMPTS delivery systems for macromolecular drugs. Expert Opin Drug Deliv 2008; 5: 1255-66.
46. Li YT, Kwon YM, Spangrude GJ, et al. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J Biomed Mater Res A 2009; 91: 209-20.
47. Dvorak HF, Nagy JA, Dvorak JT, et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109.
48. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
49. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
50. Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004; 101: 17867-72.
51. Aguilera TA, Olson ES, Timmers MM, et al. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009; 1: 371-81.
52. Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA 2010; 107: 4317-22.
53. Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using Smart pH-sensitive TAT-modified pegylated liposomes. J Drug Target 2007; 15: 538-45.
54. Kale AA, Torchilin VP. Smart drug carriers: PEGylated TATpmodified pH-sensitive liposomes. J Liposome Res 2007; 17: 197-203.
55. Deshayes S, Morris MC, Divita G, Heitz F. Interactions of primary amphipathic cell penetrating peptides with model membranes: consequences on the mechanisms of intracellular delivery of therapeutics. Curr Pharm Des 2005; 11(28): 3629-38.
56. Edenhofer F. Protein transduction revisited: novel insights into the mechanism underlying intracellular delivery of proteins. Curr Pharm Des 2008; 14(34): 3628-36.
57. Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Des 2009; 15(19): 2236-50.